Shares of Mesoblast Limited (NASDAQ:MESO) have earned a consensus rating of “Hold” from the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $11.17.
MESO has been the subject of a number of analyst reports. BidaskClub cut Mesoblast Limited from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Credit Suisse Group set a $11.00 price target on Mesoblast Limited and gave the company a “hold” rating in a report on Tuesday, July 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast Limited in a report on Thursday, June 8th. Zacks Investment Research upgraded Mesoblast Limited from a “sell” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Tuesday, May 23rd. Finally, Maxim Group set a $14.00 target price on Mesoblast Limited and gave the stock a “buy” rating in a report on Thursday, May 25th.
Mesoblast Limited (NASDAQ MESO) traded up 3.01% on Wednesday, hitting $6.84. The stock had a trading volume of 3,066 shares. Mesoblast Limited has a 1-year low of $4.01 and a 1-year high of $12.50. The firm’s market cap is $544.08 million. The firm’s 50-day moving average price is $7.60 and its 200-day moving average price is $8.14.
TRADEMARK VIOLATION WARNING: This report was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://stocknewstimes.com/2017/08/09/brokerages-set-mesoblast-limited-nasdaqmeso-target-price-at-11-17-updated-updated.html.
An institutional investor recently raised its position in Mesoblast Limited stock. Princeton Capital Management Inc. increased its stake in Mesoblast Limited (NASDAQ:MESO) by 15.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the period. Princeton Capital Management Inc. owned approximately 0.20% of Mesoblast Limited worth $1,398,000 as of its most recent SEC filing. 2.91% of the stock is owned by institutional investors.
Mesoblast Limited Company Profile
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.
